Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients |
| |
Authors: | Takashi Hattori Takashi Mine Nobukazu Komatsu Akira Yamada Kyogo Itoh Hitoshi Shiozaki Kiyotaka Okuno |
| |
Affiliation: | (1) Department of Surgery, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama Osaka, 589-8511, Japan;(2) Multidisciplinary Treatment Center, Kurume University School of Medicine, Kurume, Japan;(3) Department of Immunology, Kurume University School of Medicine, Kurume, Japan;(4) Cancer Vaccine Division of Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan |
| |
Abstract: | To investigate the safety and immunological responses of personalized peptide vaccination in combination with oral administration of UFT and UZEL for metastatic colorectal carcinoma (mCRC), fourteen patients were enrolled in the present study. Peptides were determined based on the presence of peptide-specific cytotoxic T lymphocyte precursors and IgG in each patient. A maximum of four peptides were subcutaneously administered weekly with UFT (300 mg/m2 day−1) and UZEL (75 mg/day) for 4 weeks, followed by 1 week of rest. This therapy was well-tolerated although there was a grade-3 skin reaction at the vaccination site in one patient. An increase in peptide-specific interferon-γ production or peptide-specific IgG after the tenth vaccination was observed in nine of ten or eight of ten patients tested, respectively. IgG responses were well correlated with overall survival (P = 0.0215). The safety and immunological responsiveness of the present therapy suggest that this combination would be of clinical benefit for mCRC patients, and further trials are merited. T. Hattori and T. Mine equally contributed to this work. |
| |
Keywords: | Peptide vaccine Metastatic colorectal cancer Personalized treatment Cytotoxic T lymphocyte Peptide specific IgG response |
本文献已被 SpringerLink 等数据库收录! |
|